SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Third, peroxisome proliferator-activated receptor alpha (PPAR-α), activated when SGLT2-i is administered [47], increases the production of ApoA-1, which eventually leads to the suppression and improvement of NAFLD [48].